Dr. Gallagher is a proven entrepreneur, operator, and investor, with more than 25 years of experience in commercial, drug development, and business development roles. She is currently a partner with New Enterprise Associates. Gallagher is the lead director of Atara Biotherapeutics and AnaptysBio and a director at Atterocor. She was previously the chairman of eFFECTOR Therapeutics and a director at Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion. Before joining NEA, she was a venture partner with Frazier Healthcare.
From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals, which developed the first-in-class cancer therapeutic, CAL-101, now known as Zydelig. As Calistoga's CEO, Gallagher raised $80 million in venture financing and led the company's sale to Gilead Sciences in 2011 for $375 million and a total consideration of $600 million. Gilead continued to rapidly advance registration trials of Zydelig in patients with certain types of leukemia and lymphoma. Zydelig was approved in the US and Europe in 2014 for three indications simultaneously.
Gallagher began her career in sales and marketing at Eli Lilly in 1989. She also held various commercial roles at Amgen, Agouron Pharmaceuticals and she led global marketing planning for oncology and ophthalmology at Pfizer. She was the Rituxan development team leader at Idec Pharmaceuticals, and subsequently with Biogen Idec. In this role, she worked closely with teams at Genentech and Roche to define the trial strategy that provided the basis for the broad use of RITUXAN today.
She studied chemistry at Vanderbilt University and then pursued a clinical background, attaining Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.